CASI Pharmaceuticals (US: CASI)

Last close As at 12/07/2024

1.23

0.00 (0.00%)

Market capitalisation

172m

Edison Investment Research is terminating coverage on CASI Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

CASI Pharmaceuticals — Evomela sales drive guidance upgrade

Healthcare | Update

CASI Pharmaceuticals — Continuing to execute

Healthcare | Update

CASI Pharmaceuticals — Evomela sales going strong into 2021

Share Price Performance

Financials

Edison Investment Research is terminating coverage on CASI Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Update

Healthcare

CASI Pharmaceuticals — Evomela shows a strong launch

Update

Healthcare

CASI Pharmaceuticals — Evomela launch underway

Update

Healthcare

CASI Pharmaceuticals — Executing on China rollout

Update

Healthcare

CASI Pharmaceuticals — Evomela approved in China

Initiation

Healthcare

CASI Pharmaceuticals — Riding the wave of Chinese reform